company-logo

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma Dividend Announcement

Lyell Immunopharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
Stay tuned for updates on Lyell Immunopharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Lyell Immunopharma Dividend History

Lyell Immunopharma Dividend Yield

Lyell Immunopharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Lyell Immunopharma stock? Use our calculator to estimate your expected dividend yield:

Lyell Immunopharma Financial Ratios

P/E ratio-1.15
PEG ratio0.05
P/B ratio0.44
ROE-34.64%
Payout ratio0.00%
Current ratio13.43
Quick ratio13.43
Cash Ratio2.99

Lyell Immunopharma Dividend FAQ

Does Lyell Immunopharma stock pay dividends?
Lyell Immunopharma does not currently pay dividends to its shareholders.
Has Lyell Immunopharma ever paid a dividend?
No, Lyell Immunopharma has no a history of paying dividends to its shareholders. Lyell Immunopharma is not known for its dividend payments.
Why doesn't Lyell Immunopharma pay dividends?
There are several potential reasons why Lyell Immunopharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Lyell Immunopharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Lyell Immunopharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Lyell Immunopharma a dividend aristocrat?
Lyell Immunopharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Lyell Immunopharma a dividend king?
Lyell Immunopharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Lyell Immunopharma a dividend stock?
No, Lyell Immunopharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Lyell Immunopharma stocks?
To buy Lyell Immunopharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Lyell Immunopharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.